CUMULATIVE INDEX 2000

Volume 18

February	METABOLIC MYOPATHIES, pages 1–272
May	STROKE, pages 273–516
August	CLINICAL NEUROBEHAVIORAL TOXICOLOGY, pages 517–771
November	DEMENTIA, pages 773–1044

Note: Page numbers of article titles are in **boldface** type.

Aβ protein, in Alzheimer's disease, production of, 905–908
Abuse, drugs of, as developmental neurotoxins, 545–552
Acetylcholine, neuronal effect of, 520–521
Acetylcholinesterase inhibitors, for Alzheimer's disease, 808–813
Acetylsalicylic acid (aspirin), in stroke prevention, 346–348
  failure of, 353
Acid maltase deficiency, 151–157
  clinical features of, 154
  electrophysiologic testing in, 155
  genetics of, 61–62, 65, 157
  glycogen metabolism and, 153
  histopathology of, 156–157
  laboratory features of, 155
  pathogenesis of, 157
  subtypes of, 154
  treatment of, 157
  versus other glycogen storage diseases, 144, 151–152
Acidosis, lactic, in metabolic myopathies, 55, 114–115
  metabolic, in mitochondrial myopathies, 110
Ackee, unripe, ingestion of, intoxication after, 726–727
Aconitase deficiency, myoglobinuria in, 221
Acquired immunodeficiency syndrome. See *Human immunodeficiency virus infection.*
Acute alcohol myopathy, toxin-induced, 705
Acute steroid myopathy, toxin-induced, 702–703
Acyl-coenzyme A dehydrogenase deficiencies, 179–181
  molecular diagnosis of, 75–81
  myoglobinuria in, 221
Adenosine triphosphate, depletion of, in myoglobinuria, 217–218
  generation of, 217–218
  hydrolysis of, in exercise, 16–18, 20
Adenylate deaminase deficiency, versus glycogen storage diseases, 143–144
Adrenal gland, dysfunction of, myopathies in, 209–211
Aerobic exercise training, in metabolic myopathies, 27–29
Affect, neurobiology of, 650–652
Affect disorders, toxins in, **649–664.** See also *Mood disorders of, toxins in.*
African Americans, sickle cell disease in, 279–280
  stroke in, **273–290.** See also *Stroke, in African Americans.*
  survival disadvantage in, 273
Age, as factor in stroke in Hispanic Americans, 298–299
  as factor in stroke outcome, 455–456
Aging, **789–805**
  normal, 790–791
  normal cognitive, 775
AIDS wasting syndrome. See *Human immunodeficiency virus infection, wasting syndrome in.*

Airway management, following stroke, in ICU, 439–441
Alcohol abuse, brain maldevelopment caused by, 549–551
  myoglobinuria caused by, 227–228
  myopathy caused by, 703–706
  stroke in Hispanic Americans caused by, 301
Aldolase deficiency, 64, 71–72, 142–143
Alzheimer's disease, **789–805**
  Aβ protein in, production of, 905–908
  aging to, continuum from, 789–790
  antiamylojd for, 818–819
  anti-inflammatory agents for, 814–816
  antioxidants for, 817–818
  biomarkers of, 781–783, 800
  brain lesions in, biochemical nature of, 903–905
  cholinergic agents for, 808–813
  clinical diagnosis of, 797–800
  congophilic angiopathy in, 852
  early, versus end-stage disease, 854–856
  epidemiology of, 797
  estrogen replacement therapy for, 816–817
  familial, deciphering genotype to phenotype conversions of, 909–914
  genetics of, **903–921**
  granulovacuolar bodies in, 852–853
  grossly visible findings in, 847–848
  Hirano body in, 853
  microscopic changes in, 848–853
  mild, 776–777
  molecular pathology of, **903–921**
  neurobehavioral symptoms in, **829–846**
  neurofibrillary tangles in, 848–850
  neuropathologic diagnosis of, criteria for, 853–854
  neuropathology of, **847–864**
  neuropsychiatric disorders in, and rapid cognitive decline, 834
    as contributing factor, 832–833
    cholinergic therapy for, 837–838
    disease-modifying therapy effects on, 838–839
    during disease progression, frequency of, 835
    effects on function, 835
    prevalence of, 831–832
    psychotropic agents for, 839–842
    recurrence of, 834
    types of, 830–831
  neuropsychiatric symptoms in, **829–846**
    assessment of, instrumentation in, 831
    fluctuation of, 833–834
    institutionalization due to, 836
    multiplicity of, 833
    neurobiologic correlates of, 836–837
  neurotrophic agents for, 819–820
  nicotinic acetylcholine receptor agonists for, 814
  onset of, neuropsychiatric disorders in, 832–833
  pathogenetic cascade of, 914
  preclinical, mild cognitive impairment versus, 775–776
  prediction of, mild cognitive impairment imaging and, 891–892
  prevention of, ethical issues related to, 1012–1013
  selective M1 receptor agonists for, 813–814
  senile plaques in, 850–852
  synaptic loss in, 853
  treatment of, **807–827**, 915–917
    acetylcholinesterase inhibitors for, 808–813
  with Parkinson's disease and dementia with Lewy bodies, 856–857
Aminoaciduria, in mitochondrial myopathies, 110
21-Aminosteroids, in myoglobinuria, 232
Amiodarone, neuropathies caused by, 688
AMPD genes, mutations of, 186–189
Amphetamine(s), intracerebral hemorrhage caused by, 422–423
  myoglobinuria due to, 228
Anaerobic glycogenolysis, in ATP generation, in exercise, 17–18
Anaerobic metabolism, in chronic obstructive pulmonary disease, 247–248
  in HIV infection, 250
Ancrod, for stroke, 392–393
Andersen's disease. See *Branching enzyme deficiency.*
Anemia, hemolytic, in aldolase deficiency, 142
  in phosphoglycerate kinase deficiency, 139–140
Anesthesia, myoglobinuria in, 226
Aneurysm(s), atrial septal, stroke associated with, 325–326
Angiography, cerebral, in stroke, 363
  conventional, in stroke outcome, 464–465
  CT, in stroke outcome, 463
    spiral, in stroke, 367–368
Angiopathy, cerebral amyloid, intracerebral hemorrhage caused by, 421
  congophilic, in Alzheimer's disease, 852
Angioplasty, for stroke, 390
Animal toxins, 719–725
  black widow spider bites, 724–725
  ciguatera toxin, 723–724
  paralytic shell fish, 724
  scorpion sting, 721
  snake venoms, 719–721
  tick paralysis, 722–723
Annonaceae alkaloid toxicity, 675–676

Anorexia, in congestive heart failure, 255
Antiamyloid, for Alzheimer's disease, 818–819
Antibiotic(s), myoglobinuria due to, 227
Anticoagulant(s), in stroke prevention, 352–353
Anticonvulsant(s), myoglobinuria due to, 227
Anti-inflammatory agents, for Alzheimer's disease, 814–816
Antioxidant(s), for Alzheimer's disease, 817–818
  in myoglobinuria, 232
Antiplatelet agents, for stroke, 392
  in stroke prevention, **343–355**
    acetylsalicylic acid, 346–348
    clinical goals of, 345
    clopidogrel, 349–350
    dipyridamole, 350–352
    early trials, 344–345
    endpoints in, 345
    ticlopidine, 348–349
  in thrombus inhibition, 343–344
Antipsychotic drugs, myoglobinuria due to, 227
Antithrombolytic agents, in stroke prevention, **343–355**
Antithrombotic agents, for stroke, 390–393
Aortic arch atheroma, stroke associated with, 328–329
Aphasia, progressive nonfluent, and frontotemporal dementia, 983
Apoptosis, 525–533
  biomechanical mechanisms of, 526–531
  final common pathway of, 527
  in neurotoxic injury, 532–533
Arsenic, in mood and affect disorders, 654–655
  in peripheral neurotoxic disorders, 683–684
Arterial dissection, treatment of, 400–403
Arteriopathy(ies), nonatherosclerotic, treatment of, 399–406. See also specific disorder, e.g., *Vasospasm.*
Aspirin, in stroke prevention, 346–348
  failure of, 353
Astrocyte(s), neuronal effect of, 523–524
Ataxia, Friedreich's, 118
  in Leigh disease, 115
  in myoclonic epilepsy and ragged-red fiber disease, 114
Atheroma, aortic arch, stroke associated with, 328–329
Atherosclerosis, extracranial cerebral arterial stenosis caused by, 329
ATLANTIS rt-PA Acute Stroke Trial, 387
ATP (adenosine triphosphate), depletion of, in myoglobinuria, 217–218
  generation of, 217–218
  hydrolysis of, in exercise, 16–18, 20
ATPase gene, mutations of, in Leigh disease, 115
Atrial fibrillation, as factor in stroke outcome, 456–457
  stroke associated with, 321–323
Atrial myxoma, stroke associated with, 323
Atrial septal aneurysms, stroke associated with, 325–326
Attention, neuropsychological evaluation of, 595–596
Auditory systems, quantitative neurological examination of, 567–568
Autonomic testing, in neurobehavioral toxicology evaluation, 611
Axonal degeneration, distal, 533–535
Axonal maintenance, neuronal effect of, 522–523
Axonal transport, chemotherapeutic agents interfering with, 533–534
  industrial neurotoxins interfering with, 534
  neuronal effect of, 522–523
AZT. See *Zidovudine (AZT).*

Bacterial toxins, 730–736
  botulinum toxin, 731–733
  diphtheria, 730–731
  tetanus, 733–736
Basal ganglia neurotoxins, **665–680**
  annonaceae alkaloid, 675–676
  carbon disulfide, 669
  carbon monoxide, 671–672
  cynanide, 668–669
  hydrogen sulfide, 670
  manganese, 666–668
  methanol, 670–671
  MPTP, 674–675
  3-nitroproprionic acid, 672–674
Beck Depression Inventory, 596
Becker's muscular dystrophy, myoglobinuria in, 221–222
Bee stings, myoglobinuria due to, 229
Behavior, brain, concepts regarding, 541–544. See also *Brain, behavior of.*
  malformation versus deformation, 543–544
  measuring of, **579–599**
    criteria for, 583–584
    neuropsychological evaluation in, 586–596
      attention in, 595–596
      cognitive speed in, 594–595
      concentration in, 595–596
      direct one-to-one examination in, 589–596
      language functioning in, 593

Behavior (*continued*)
memory functioning in, 594
motor functions in, 590–591
obtaining personal information in, 587–589
patient history in, 590
perceptual functioning in, 591–592
personality evaluation in, 596
problem solving in, 593–594
referral information in, 586–587
sensory functioning in, 591–592
proportionality in, 584–586
Bias, defined, 633
in neurotoxic disorder evaluation, 633–634
information, defined, 634
selection, defined, 633
Biological neurotoxins, **719–740.** See also *Neurotoxin(s), biological.*
Biopsy, muscle, in acid maltase deficiency, 156
in branching enzyme deficiency, 130, 161
in carnitine deficiencies, 171
in debranching enzyme deficiency, 128, 159
in metabolic myopathies, 4–11, 55–56
in mitochondrial myopathies, 110–111
in myophosphorylase deficiency, 131–132
in phosphofructokinase deficiency, 136
in phosphoglycerate kinase deficiency, 139–140
in phosphorylase b kinase deficiency, 138
Biphenyl(s), polychlorinated, brain maldevelopment caused by, 554–555
Bismuth, in mood and affect disorders, 655
Bite(s), spider, black widow, 724–725
Black widow spider bites, 724–725
Blink reflex studies, in neurobehavioral toxicology evaluation, 610
Blood pressure, following stroke, 457–458
Body composition, in HIV infection, 252–253
Body temperature, following stroke, 458
Boston Diagnostic Aphasia Examination, 593
Boston Naming Test, 591
Botanical depressants, 729–730
Botanical toxins, 725–730
chickpea, 727–728
convulsants, 729–730
depressants, 729–730
Jamaican vomiting sickness, 726–727
khat, 728
lathyrism, 727–728
mushrooms, 725–726
Spanish rapeseed oil
Botulinum toxin, 731–733
Botulism, 731–733
Brain, behavior of, concepts regarding, 541–544
goals of, 542–543
exercise response in, 18–19
magnetic resonance spectroscopy of, in mitochondrial disorders, 42–43
Brain development, concepts regarding, 541–544
neurotoxin-induced alterations of programs underlying, 544
programs underlying, 541–542
Brain imaging, functional, in neurotoxicology, 624–626
neurochemical, in neurotoxicology, 626
neuropharmacologic, in neurotoxicology, 626
structural, in neurotoxicology, 623–624
Brain injury, ischemic, pathophysiology of, 955–959
Branching enzyme deficiency, 129–130, 152, 160–161
molecular diagnosis of, 64, 66
Breast implants, silicone, controversies related to, 746–750

Cachexia, cardiac, 254–257
Calcium channels, neuronal effect of, 520
Calcium influx, inhibition, following stroke, neuroprotective drugs in, 500
Carbohydrates, oxidation of, in HIV infection, 251
Carbon disulfide intoxication, 669
Carbon monoxide, in mood and affect disorders, 658–659
Carbon monoxide poisoning, 671–672
myoglobinuria in, 229
Cardiac disease, as factor in stroke in Hispanic Americans, 300
Cardiac output, in exercise, 19
Cardioembolic stroke, in African Americans, 278–279
Cardioembolism, stroke associated with, 321–329
Cardiomyopathy, dilated, stroke associated with, 324
in branching enzyme deficiency, 130
in carnitine deficiencies, 172–173
in carnitine palmitoyltransferase deficiency, 175
Carnitine deficiencies, 169–178
in carnitine palmitoyltransferase deficiency, 143, 174–178, 221
molecular diagnosis of, 72–74, 76
primary, 74
myopathic, 171–172
systemic, 72, 172–174
secondary, 174
versus normal metabolism, 170

Carnitine palmitoyltransferase deficiency, 174–178
molecular diagnosis of, 73–74, 76
myoglobinuria in, 221
versus glycogen storage diseases, 143
Carnitine-acylcarnitine translocase translocase deficiency, 73–74, 178
Carotid angioplasty-stenting (CAS), for carotid artery stenosis, 335–336
Carotid artery stenosis, carotid angioplasty and stenting and, 335–336
endarterectomy for, 329–335
historical background of, 329
internal, 329
stroke associated with, 329–336
Carotid duplex scanning, in stroke outcome, 464
Carpopedal spasm, in hypoparathyroid myopathy, 207
Caspase activation, pathways leading to, 528
Catecholamine(s), neuronal effect of, 522
Cell death, mechanisms of, **525–540**
Ceramide pathway, 530–531
Ceramide signaling, 530–531
Cerebellar ataxia, in Leigh disease, 115
in myoclonic epilepsy and ragged-red fiber disease, 114
Cerebral amyloid angiopathy, intracerebral hemorrhage caused by, 421
Cerebral angiography, in stroke, 363
Cerebral artery infarction, malignant middle, hypothermia and hemicraniectomy in, treatment of, 501–503
Cerebral ischemia, mechanisms of, 476–482
basic, 476–477
in animal model studies, 477
in drug development, 477–479
translation to clinical trials, 479–482
Cerebral venous thrombosis, stroke-related, treatment of, 410–412
Chelation therapy, for myoglobinuria, 231–232
Chemical(s), in mood and affect disorders, 656
Chemotherapeutic agents, axonal transport affected by, 533–534
Chickpea poisoning, 727–728
Chloramphenicol, toxicity of, 710
Chlorinated hydrocarbons, poisoning with, EEG in, 603
Chlorine channels, neuronal effect of, 520
Cholinergic agents, for Alzheimer's disease, 808–813
for neuropsychiatric disorders in Alzheimer's disease, 837–838
Chromosome 17, parkinsonism linked to, 859–860
Chronic alcohol myopathy, toxin-induced, 705–706
Chronic obstructive pulmonary disease, wasting syndrome in, 245–249
clinical features of, 246
malnutrition in, 246
reduced caloric intake in, 248
weight loss in, 246–248
Chronic organophosphate-induced neuropsychiatric disorder (COPIND), controversies related to, 750–756
Chronic steroid myopathy, toxin-induced, 702
Chvostek's sign, in hypoparathyroid myopathy, 207
Cigarette smoking, as factor in stroke, 312–313
Ciguatera toxin, 723–724
Cisplatin, neuropathies caused by, 689
Clopidogrel, in stroke prevention, 349–350
Clozapine, myopathy caused by, 711–712
Coagulopathy(ies), intracerebral hemorrhage caused by, 421–422
Cocaine, brain maldevelopment caused by, 551–552
intracerebral hemorrhage caused by, 422–423
myoglobinuria due to, 228
Coenzyme Q10 deficiency, myoglobinuria in, 221
Cognitive dysfunction, in dementia with Lewy bodies. See *Dementia, with Lewy bodies.*
Cognitive enhancing drugs, dementia prevention through, ethical issues related to, 1016
Cognitive impairment, mild, 775–776, **789–805**
clinical outcome of, 793–795
imaging of, in Alzheimer's disease diagnosis, 891–892
neuroimaging of, 795–796
neuropathology of, 796–797
rating scale for, 795
Cognitive speed, neuropsychological evaluation of, 594–595
Colchicine, myopathy caused by, 710–711
Cold exposure, myoglobinuria in, 224–225
Compartment syndrome, myoglobinuria in, 225–226
Complexes I to V, deficiencies of. See *Mitochondrial myopathies and encephalopathies.*
Comprehensive Clinical Evaluation Program (CCEP), of Department of Defense for Persian Gulf veterans, 753
Computed tomography (CT), following stroke, ischemic changes, 461–463
in dementia, 890–891
in stroke, 358–359
x-ray, in neurotoxicology, 616

Computed tomography (CT) angiography, in stroke outcome, 463
spiral, in stroke, 367–368
Concentration, neuropsychological evaluation of, 595–596
Confidence intervals, in neurotoxic disorder evaluation, 638–639
Confounding, in neurotoxic disorder evaluation, 636–638
Congestive heart failure, wasting syndrome in, 254–257
Congophilic angiopathy, in Alzheimer's disease, 852
Consciousness, altered, following stroke, 457
Conventional angiography, in stroke outcome, 464–465
Convulsant(s), botanical, 729–730
Cori-Forbes disease. See *Debranching enzyme deficiency.*
Cortical gray matter, incomplete infarcts of, in vascular dementia, 966
Corticosteroid(s), myopathy caused by, 701–703
Corticosteroid myopathy, 209–211
Cramps, in myoadenylate deaminase deficiency, 185
in phosphofructokinase deficiency, 135
in phosphoglycerate kinase deficiency, 139
in phosphoglycerate mutase deficiency, 140–141
in phosphorylase b kinase deficiency, 138
Cranial neuropathy, in Leigh disease, 115
Crush syndrome, myoglobinuria in, 225–226
CT. See *Computed tomography (CT).*
Cushing's disease, myopathy in, 210–211
Cyanide intoxication, 668–669
Cyclosporine, toxicity of, 710
Cytochrome c oxidase, deficiency of, myoglobinuria in, 221
testing for, in mitochondrial myopathies, 111
Cytokine(s), production of, in AIDS wasting syndrome, 253

Death receptor pathway, 528–529
Debranching enzyme deficiency, 126, 128–129, 152, 158–160
molecular diagnosis of, 64–66
myoglobinuria in, 220
Defibrinogenating agents, for stroke, 392–393
Dementia, biomarkers of, 781–783
defined, 774–775
diagnosis of, common reactions to, 998–1001
differential diagnosis of, 777–781
SPECT and PET in, 887–890
epidemiology of, **923–949**
uses and misuses of, 923–924
ethical issues in, **1011–1022**
advance planning in, 1014–1016
Alzheimer's disease prevention, 1012–1013
dementia prevention through cognitive enhancing drugs, 1016
diagnostic truth telling in, 1014
distributive justice, 1018–1019
natural dying, 1019–1021
preventive medications, 1016–1017
research-related, 1013–1014
respectful caring, 1017–1018
restrictions on driving privileges, 1016–1017
family issues in, **993–1010**
end-of-life decisions, 1007
family assessment, 1001–1002
family coping strategies, 1001
family education, 1002–1003
family resources, 1005–1006
office visits, 995–997
problem identification, 995
support for care decisions, 1003–1004
use of formal or paid services, 1004–1005
frontotemporal, 780–781, 859–860, **979–992.** See also *Frontotemporal dementia.*
in myoneurogastrointestinal disorder and encephalopathy, 116–117
in Parkinson's disease, **865–883**
clinical features of, 868–872
clinical management, 875–877
cortical pathologies of, 867
diagnosis of, 872–875
extracerebral pathology of, 867
neuropathology of, 865–868
prevalence of, 865
incidence of, 930–932
Lewy bodies and, 866–867
multiinfarct, 860–861
neuroimaging in, **885–901**
CT, 890–891
functional brain imaging, 886–887
future trends in, 894–895
MRI, 890–891
PET, 886–890
SPECT, 886–890
techniques in, 894–895
traditional approach to, 886
normal cognitive aging versus, 775
nosology of, **773–788**
onset of, determination of, 931

presence of, establishment of, 774–777
prevalence of, 925–930
protective factors in, 941–943
risk factors for, 932–941
semantic, 983–984
vascular, 780, **951–977**
complete infarcts in, 964
diagnosis of, 959–963
events leading to, 953–955
historical conceptualization of, 958
incidence of, 952–953
incomplete infarcts of cortical gray matter in, 966
incomplete infarcts of white matter in, 964–966
neuroimaging of, 963–966
paradigm shift in, 969–970
physiologic and structural data related to, 958–959
prevalence of, 952–953
problems associated with, 951–952
stroke and, in African Americans, 283–284
treatment of, 967–969
white matter changes in, 892–894
with Lewy bodies, 779–780
Alzheimer's disease with Parkinson's disease and, 856–857
clinical features of, 871–872
congitive dysfunction in, 869–870
described, 865
neuropsychiatric features in, 871
Denaturing gradient gel electrophoresis, in mutation detection, 59
Depressant(s), botanical, 729–730
Depression, 781
Diabetes mellitus, as factor in stroke, 311–312
in Hispanic Americans, 300
DIC. See *Disseminated intravascular coagulation (DIC).*
Didanosine, toxicity of, 709
Diffuse cortical Lewy body disease, 856–857
Diffusion-weighted imaging, in stroke outcome, 465–467
Diphtheria, 730–731
Dipyridamole, in stroke prevention, 350–352
Dissection, arterial, treatment of, 400–403
Disseminated intravascular coagulation (DIC), stroke-related, treatment of, 409
Distal axonal degeneration, 533–535
Diuretic(s), in myoglobinuria, 231
myoglobinuria due to, 227
DNA, depletion of, 88, 115–116
domal, neuronal effect of, 518–519
mitochondrial, disorders of. See *Mitochondrial myopathies and encephalopathies.*
DNA analysis, in mitochondrial myopathies, 111–112
Docetaxel, neuropathies caused by, 690
Doppler ultrasonography, transcranial, in stroke outcome, 463–465
Drug(s), intracerebral hemorrhage caused by, 422–423
myoglobinuria due to, 226–228
myopathies due to, 209–210
neuropathies caused by, 687–691. See also specific drugs.
neuroprotective, following stroke, 499–501
in animals, versus humans, **475–493**
of abuse, as developmental neurotoxins, 545–552
Duchenne's muscular dystrophy, exercise response in, 28, 30
myoglobinuria in, 221–222

E6010, for stroke, 389–390
Echocardiography, in stroke, 368–370
Echo-planar imaging, in stroke outcome, 465–467
Edema, of muscles, in hypothyroid myopathy, 204
Education, family, in dementia, 1002–1003
EEG. See *Electroencephalography (EEG).*
Electrical burns, myoglobinuria in, 226
Electroencephalography (EEG), in neurobehavioral toxicology evaluation, 602–604
Electrolyte imbalance, myoglobinuria in, 225
Electromyography (EMG), in acid maltase deficiency, 155
in branching enzyme deficiency, 161
in debranching enzyme deficiency, 128, 159
in familial hypokalemic periodic paralysis, 196–197
in metabolic myopathies, 4
in neurobehavioral toxicology evaluation, 604–609
Electron transport chain, myopathy caused by, 700–701
Electrophoresis, in mutation detection, 59
Electrophysiologic testing, in metabolic myopathies. See *Electromyography; Nerve conduction studies.*
Electrophysiological evaluations, autonomic testing in, 611
blink reflex studies in, 610
EEG, 602–604
EMG in, 604–609

Electrophysiological evaluations (*continued*)
evoked potentials in, 604
in neurobehavioral toxicology evaluation, **601–613**
quantitative sensory testing in, 611–612
repetitive nerve stimulation, 609–620
EMG. See *Electromyography (EMG).*
Encephalopathy(ies), in carnitine palmitoyltransferase deficiency, 175
mitochondrial. See *Mitochondrial myopathies and encephalopathies.*
painters', controversies related to, 742–746
solvent, controversies related to, 742–746
subacute necrotizing (Leigh disease), 85–87, 115, 117–118
with myoneurogastrointestinal disorder (MNGIE), 87, 116–117
Endarterectomy, for carotid stenosis, 329–330
asymptomatic, 333–335
symptomatic, 330–333
Endocarditis, infective, stroke associated with, 326–327
Endocrine myopathies, **203–213**
adrenal, 209–211
parathyroid, 207–209
thyroid, 47, 203–207
End-stage disease, versus early Alzheimer's disease, 854–856
Energy expenditure, in chronic obstructive pulmonary disease, 247–248
in HIV infection, 250–251
Energy state, neuronal effect of, 519
Envenomations, myoglobinuria in, 228–229
Environment, enriched, following stroke, 503–504
Enzyme inhibition, neuronal effect of, 519
Eosinophilia—myalgia syndrome, 708
Ependymal cells, neuronal effect of, 523–524
Epilepsy, behaviors related to, 580
myoclonic, and ragged-red fiber disease, 114
Estrogen replacement therapy, for Alzheimer's disease, 816–817
Ethic(s), research, in dementia, 1013–1014
Ethical issues, in dementia, **1011–1022.** See also *Dementia, ethical issues in.*
Ethnicity, as factor in stroke, 456
incidence patterns, 296–298
mortality patterns, 295–296
defined, 292
Evoked potentials (EPs), defined, 604
in neurobehavioral toxicology evaluation, 604
Excitable membrane, neuronal effect of, 520
Excitotoxic cell injury, 533
Exercise, extreme, myoglobinuria in, 223–224
intolerance of, differential diagnosis of, 143
in aldolase deficiency, 142
in lactate dehydrogenase deficiency, 141–142
in myophosphorylase deficiency, 130–131, 134
in phosphofructokinase deficiency, 135
in phosphoglycerate mutase deficiency, 140–141
in phosphorylase b kinase deficiency, 138
magnetic resonance techniques in, 48–49
muscle responses to, **15–34**
brain response and, 18–19
evaluation of, 21–23
fatigue, 19–21, 23
force generation, 16–18
in contraction control disorders, 30–31
in energy metabolic disorders, 26–29
in glycogen storage disorders, 23–26
in mitochondrial myopathies, 26–27, 41–42
in muscle diseases, 15–16
in muscular dystrophies, 28, 30
in myoglobinuria, 218
magnetic resonance techniques for, 40–42
systemic response and, 18–19
myalgia in, in myoadenylate deaminase deficiency, 188–189
response to, in chronic obstructive pulmonary disease, 246
Exercise testing, dynamic, in metabolic myopathies, 22
glycogen storage, 24–26
mitochondrial, 27
forearm ischemic, in metabolic myopathies, 3–4, 21–22, 24, 131
Exposure assessment, in neurotoxic disorder evaluation, 639–641
Extrinsic agents, myopathy caused by, 701

Familial hypokalemic periodic paralysis, 195–198
Family coping strategies, in dementia, 1001
Family education, in dementia, 1002–1003
Family issues, in dementia, **993–1010.** See also *Dementia, family issues in.*
Family resources, in dementia, 1005–1006
Fatigue, in chronic obstructive pulmonary disease, 246
in exercise, 19–21
quantitative assessment of, 23
in myophosphorylase deficiency, 131

Fatty acid oxidation. See *Lipid(s), oxidation of.*
Fever, myoglobinuria in, 224
Finger Tapping, 591
Finger Tip Number Writing, 592
Fish toxins, myoglobinuria due to, 229
Fluid therapy, for myoglobinuria, 231
Forearm ischemic exercise test, in metabolic myopathies, 3–4, 21–22, 24, 131
Friedreich's ataxia, 118
Frontotemporal dementia, 780–781, 859–860, **979–992**
  anatomical subtypes of, 984
  clinical presentation of, 981
  differential diagnosis of, 988
  genetics of, 985–987
  historical background of, 979–980
  left versus right variants of, 984
  Neary and colleagues' consensus criteria for, 981–984
  neuroimaging in, 987–988
  nomenclature associated with, 979–980
  pathology of, 984–985
  progressive nonfluent aphasia and, 983
Fructose-1,6-bisphosphate aldolase (aldolase) deficiency, 64, 71–72, 142–143
Functional brain imaging, in dementia, 886–887
  in neurotoxicology, 624–626

GABA, neuronal effect of, 521
Gamma-aminobutyric acid (GABA), neuronal effect of, 521
Gastrointestinal disorders, in myoneurogastrointestinal disorder and encephalopathy, 87, 116–117
Gaze deviation, following stroke, 457
Gel electrophoresis, in mutation detection, 59
Gender, as factor in stroke in Hispanic Americans, 299
  as factor in stroke outcome, 456
Gene therapy, for acid maltase deficiency, 157
Genetics, in Alzheimer's disease, **903–921**
  in frontotemporal dementia, 985–987
  inheritance modes, 57–59
  mutation detection methods in, 59–61
  of acid maltase deficiency, 61–62, 157
  of acyl-coenzyme A dehydrogenase deficiencies, 75–81
  of aldolase deficiency, 64, 71–72, 143
  of branching enzyme deficiency, 64, 66, 130, 161
  of carnitine deficiencies, 72–74, 76, 172–173, 177–178
  of debranching enzyme deficiency, 64–66, 129, 159
  of glycogen storage diseases, 61–72
  of lactate dehydrogenase deficiency, 63, 71, 142
  of lipid oxidation and transport, 72–81
  of malignant hyperthermia, 89
  of mitochondrial myopathies and encephalopathies, 81–88, 106–108, 112. See also *specific disease.*
  of myoadenylate deaminase deficiency, 88–89, 186–189
  of myoglobinuria, 220–222
  of myophosphorylase deficiency, 62, 67
  of paramyotonia congenita, 200–201
  of phosphofructokinase deficiency, 63, 68–69, 137
  of phosphoglycerate kinase deficiency, 63, 69, 71, 140
  of phosphoglycerate mutase deficiency, 63, 71, 141
  of phosphorylase b kinase deficiency, 62, 68, 139
  of phosphorylase deficiency, 134
  of potassium-sensitive periodic paralysis, 198–199
  of trifunctional protein deficiency, 78–79
Glial cell injury, in neurotoxicity, 534–535
Glucocorticoid myopathy, 209–211
Glucose, serum, in stroke outcome, 460
Glucose-6-phosphatase, deficiency of, 152
  in glycogen metabolism, 127
Glucose-6-phosphate dehydrogenase deficiency, myoglobinuria in, 221
1,4-Glucosidase deficiency. See *Acid maltase deficiency.*
Glutamate/aspartate, neuronal effect of, 521
Glutaric acidemia, 81
Glutathione, in myoglobinuria, 232
Glycine, neuronal effect of, 521
Glycogen, in muscle biopsy, 7, 10–11
  metabolism of, 127, 153
    myopathy caused by, 700
Glycogen storage diseases, **125–150**
  acid maltase deficiency (type II). See *Acid maltase deficiency.*
  aldolase deficiency (type XII), 64, 71–72, 142–143
  branching enzyme deficiency (type IV), 64, 66, 129–130, 152, 160–161
  debranching enzyme deficiency (type III). See *Debranching enzyme deficiency.*
  differential diagnosis of, 143–144
  dynamic, 151
  exercise response in, 23–26
  genetics of, 61–72

Glycogen storage diseases (*continued*)
glucose-6-phosphatase deficiency (type I), 151–152, 152
glycogen metabolism and, 153
lactate dehydrogenase deficiency (type XI). See *Lactate dehydrogenase deficiency.*
liver phosphorylase deficiency (type VI), 152
magnetic resonance techniques in, 44–47
molecular diagnosis of, 61–72
myoglobinuria in, 220
myophosphorylase deficiency (type V). See *Myophosphorylase deficiency.*
numbering system for, 126, 152
phosphofructokinase deficiency (type VII). See *Phosphofructokinase deficiency.*
phosphoglycerate kinase deficiency (type IX). See *Phosphoglycerate kinase deficiency.*
phosphoglycerate mutase deficiency (type X). See *Phosphoglycerate mutase deficiency.*
phosphorylase b kinase deficiency (type VIII). See *Phosphorylase b kinase deficiency.*
static, 151
treatment of, 144
types of, 125–126, 151–152
Glycogenolysis, in ATP generation, in exercise, 17–18
metabolism of, 153
Glycolysis, 127
in ATP generation, in exercise, 17–18
Granulovacuolar bodies, in Alzheimer's disease, 852–853
Granzyme B-perforin pathway, 531–532
Graves' disease, myopathy in, 205–206
Grooved Pegboard Test, 591
Growth factors, endogenous, following stroke, 504
Growth hormone, excess of, in congestive heart failure, 256–257
Gulf War syndrome, controversies related to, 750–756

Haff disease, myoglobinuria in, 229
Halstead Category Test, 593
Halstead's Finger Oscillation Test (Finger Tapping), 591
Handynometer, 591
Headache(s), migraine, stroke associated with, treatment of, 406–408
Healthy hire effect, 634
Healthy worker effect, 634–635
Healthy worker survivor effect, 634
Heart failure, congestive, wasting syndrome in, 254–257
Heart valves, prosthetic, stroke associated with, 326
Heat exposure, myoglobinuria in, 224
Heavy metal toxins, in peripheral neurotoxic disorders, 683–686
Hematologic disorders, stroke-related, treatment of, 408–410
Hematologic testing, in stroke, 370–372
Hemicraniectomy, in malignant middle cerebral artery infarction, 502–503
Hemodialysis, in myoglobinuria, 232
Hemolytic anemia, in aldolase deficiency, 142
in phosphoglycerate kinase deficiency, 139–140
Hemorrhage, intracerebral, **419–438.** See also *Intracerebral hemorrhage.*
Hemorrhagic stroke, in African Americans, 277–278
Heparin(s), for stroke, 390–392
Heparinoid(s), for stroke, 390–392
Hexacarbon(s), neuropathies caused by, 690–691
Hirano body, in Alzheimer's disease, 853
Hispanic Americans, ethnicity, social concepts of, 292
ethnicity of, biologic concepts of, 292
in United States, demographic profile of, 292–294
population of, 291
stroke in, **291–307.** See also *Stroke, in Hispanic Americans.*
Hoffman's syndrome, in hypothyroid myopathy, 204
Holter monitor, in stroke, 370
Human immunodeficiency virus infection, wasting syndrome in, 249–254
body composition in, 252–253
clinical features of, 249–250
cytokine production in, 253–254
mechanisms of, 251–252
metabolism in, 250–251
substrate oxidation rates in, 251
Hydrocarbon(s), poisoning with, EEG in, 603
Hydrogen sulfide intoxication, 670
3-Hydroxy-3-methyl glutaryl CoA reductase inhibitors, myoglobinuria due to, 226–227
Hypercalcemia, in hyperparathyroid myopathy, 208–209
Hypercoagulable states, stroke-related, treatment of, 408–409
Hyperdense artery sign, defined, 461
in stroke outcome, 461
Hypermetabolism, in chronic obstructive pulmonary disease, 247–248

in congestive heart failure, 256–257
in HIV infection, 250–253
Hypernatremia, myoglobinuria in, 225
Hyperparathyroidism, myopathy in, 208–209
Hyperpyrexia, myoglobinuria in, 224
Hypertension, as factor in stroke, 310–311
in Hispanic Americans, 299–300
intracerebral hemorrhage caused by, 420–421
treatment of, 424–426
Hyperthermia, malignant, 89, 221–222
myotoxicity of, 713–714
Hyperthyroidism, myopathies in, 205–207
Hypertriglyceridemia, in HIV infection, 252
Hypocalcemia, in hypoparathyroid myopathy, 207
Hypodensity, parenchymal, in stroke outcome, 462–463
Hypoglycemia, in acyl-coenzyme A dehydrogenase deficiencies, 179–180
in carnitine palmitoyltransferase deficiency, 175
in debranching enzyme deficiency, 158–160
Hypokalemia, myoglobinuria in, 225
periodic paralysis in, 195–198
Hyponatremia, myoglobinuria in, 225
Hypoparathyroidism, myopathy in, 207–208
Hypophosphatemia, myoglobinuria in, 225
Hypothermia, in malignant middle cerebral artery infarction, treatment of, 501–502
Hypothyroidism, myopathies in, 47, 204–205
Hypotonia, in acid maltase deficiency, 154
in acyl-coenzyme A dehydrogenase deficiencies, 179–180
in branching enzyme deficiency, 129
in myoadenylate deaminase deficiency, 185
Hypoxia, cellular, in congestive heart failure, 255–256

ICP. See *Intracranial pressure (ICP)*.
ICU. See *Intensive care unit (ICU)*.
Immobilization, myoglobinuria in, 226
Individual Neuropsychological Test, 596
Industrial neurotoxins, axonal transport affected by, 534
Infection(s), myoglobinuria in, 229
Infective endocarditis, stroke associated with, 326–327
Inflammation, in stroke outcome, 459–460
myopathy-related, 708
Influenza, myoglobinuria in, 229
Information bias, defined, 634
Inheritance, of metabolic myopathies, 57–59
mitochondrial, 57–59, 106–108
Insular ribbon sign, in stroke outcome, 461–462
Intensive care unit (ICU), in stroke, management of, **439–454.** See also *Stroke, treatment of, in ICU.*
Interferon-α, production of, in AIDS wasting syndrome, 253
Interleukin(s), production of, in AIDS wasting syndrome, 253
Intracerebral hemorrhage, **419–438**
causes of, 420–423
cerebral amyloid angiopathy and, 421
coagulopathies and, 421–422
diagnosis of, 423
drug-related, 422–423
epidemiology of, 419–420
hypertension and, 420–421
treatment of, 424–426
increased ICP in, treatment of, 427–428
outcome in, 431
parenchymal, described, 419
prior stroke and, 422
research on, new directions in, 431–433
risk factors for, 420–423
structural lesions and, 422
thrombolysis-related, 431
treatment of, 423–431
blood pressure management, 427
medical, initial, 424
new directions in, 431–433
surgical, 428–431
Intracranial pressure (ICP), increased, following stroke, treatment of, in ICU, 443–444
treatment of, 427–428
Intravenous thrombolytic therapy, for stroke, 382–388
Ischemia, cerebral. See *Cerebral ischemia.*
determinants of, 955–958
Ischemic brain injury, pathophysiology of, 955–959
Ischemic forearm exercise testing, in metabolic myopathies, 3–4, 21–22, 24, 131

Jamaican vomiting sickness, 726–727

Kearns-Sayre disease, 113–114, 116
3-Ketoacyl-coenzyme A deficiency, 221
Khat poisoning, 728
Kidney failure, in myoglobinuria, 230–232

Kocher-Debre-Semelaigne syndrome, 204
Krebs' cycle, myopathy caused by, 700–701

Laboratory testing, in stroke, 370–372
Lactate dehydrogenase deficiency, 141–142, 152
  molecular diagnosis of, 63, 71
  myoglobinuria in, 220
Lactic acidosis, in metabolic myopathies, 55
  in mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), 114–115
Lacunar infarction, in African Americans, 277
Lambert-Eaton myasthenic syndrome (LEMS), repetitive nerve stimulation in, 609
Language functioning, neuropsychological evaluation of, 593
Lathyrism, 727–728
Lead, brain maldevelopment caused by, 552–553
  in mood and affect disorders, 652–653
  in peripheral neurotoxic disorders, 684–685
Lead poisoning, EEG in, 603
Left ventricular thrombus, stroke associated with, 323–324
Legionellosis, myoglobinuria in, 229
Leigh disease, 85–87, 115, 117–118
Lentiform obscuration, in stroke outcome, 461–462
Leukodystrophy, in myoneurogastrointestinal disorder and encephalopathy, 87, 116–117
Lewy bodies, and dementia, 866–867
  and Parkinson's disease, 865–866
  dementia with, 779–780. See also *Dementia, with Lewy bodies.*
    Alzheimer's disease with Parkinson's disease and, 856–857
Lightning injury, myoglobinuria in, 226
Lipid(s), as factor in stroke, 313–315
    in Hispanic Americans, 300–301
  in muscle biopsy, 11
  metabolism of, myopathy caused by, 700
  oxidation of, disorders of, **167–184**
    acyl-coenzyme A dehydrogenase deficiency, 179–181
    carnitine deficiencies. See *Carnitine deficiencies.*
    carnitine-acylcarnitine translocase deficiency, 73, 178
    molecular diagnosis of, 72–81
    myoglobinuria in, 220–221
    versus normal lipid metabolism, 168–169
    in ATP generation, in exercise, 17–18
    in HIV infection, 251
Lipid lowering agents, myopathy caused by, 706–708
Lipid-lowering agents, myoglobinuria due to, 226–227
Lipoamide dehydrogenase deficiency, myoglobinuria in, 221
Lithium, myoglobinuria due to, 227
Liver, dysfunction of, in branching enzyme deficiency, 130
    in carnitine palmitoyltransferase deficiency, 175
    in debranching enzyme deficiency, 126
    in phosphorylase b kinase deficiency, 137–138
  transplantation of, in branching enzyme deficiency, 161
Liver phosphorylase deficiency, 152

M1 receptor agonists, for Alzheimer's disease, 813–814
McArdle's disease. See *Myophosphorylase deficiency.*
Magnetic resonance angiography (MRA), in stroke, 366–367
  in stroke outcome, 467
Magnetic resonance (MR) diffusion imaging, in stroke, 360–361
Magnetic resonance imaging (MRI), in dementia, 890–891
  in neurotoxicology, 616–619
  in stroke, 359
  in stroke outcome, 465–467
Magnetic resonance spectroscopy and imaging, in metabolic myopathies, **35–52**
  clinical use of, 47–49
  glycolytic, 44–47
  mitochondrial, 39–44
  principles of, 35–39
  thyroid, 47
Malabsorption, in congestive heart failure, 255–256
Malignant hyperthermia, 89, 221–222
  myotoxicity of, 713–714
Malnutrition, in chronic obstructive pulmonary disease, 246
Manganese intoxication, 666–668
  in mood and affect disorders, 654
Mannitol, in myoglobinuria, 231
Maternal inheritance, of mitochondrial diseases, 57–59, 106–108
Medicolegal issues, in toxin-induced mood and affect disorders, 659–661
Megestrol acetate, in wasting syndrome, in HIV infection, 252

MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes), 114–115
Membrane(s), excitable, neuronal effect of, 520
Memory for Design Test, 592
Memory functioning, neuropsychological evaluation of, 594
Mental status, quantitative neurological examination of, 565–566
Mercury, in mood and affect disorders, 653–654
in peripheral neurotoxic disorders, 685–686
MERRF (myoclonic epilepsy and ragged-red fiber disease), 114
Metabolic myopathies, adrenal, 209–211
clinical features of, 2
diagnosis of, **1–13.** See also specific diseases.
biochemical, 56
electrophysiologic testing in. See *Electromyography; Nerve conduction studies.*
forearm ischemic exercise test in, 3–4, 21, 22, 24, 131
histopathologic, 55–56
laboratory, 54–55
molecular, **53–104.** See also *Genetics.*
muscle biopsy in. See *Biopsy, muscle.*
encephalopathy with. See *Mitochondrial myopathies and encephalopathies.*
endocrine, 47, **203–213**
glycogen storage. See *Glycogen storage diseases.*
history in, 2
inheritance of, 57–59, 106–108
lipid, **167–184,** 251
magnetic resonance spectroscopy and imaging in, 22, **35–52**
mitochondrial. See *Mitochondrial myopathies and encephalopathies.*
molecular diagnosis of, **53–104**
glycogen, 61–72
inheritance modes and, 57–59
lipid oxidation, 72–81
malignant hyperthermia, 89
methods for, 59–61
mitochondrial, 81–88
myoadenylate deaminase deficiency, 88–89
versus other methods, 54–56
myoadenylate deaminase deficiency, 88–89, **185–194**
myoglobinuria, 54, **215–243**
parathyroid, 207–209
periodic paralyses, **195–202,** 206
primary, 1
secondary, 2
thyroid, 47, 203–207
tissue wasting, **245–262**
types of, 53–54
Metal(s), heavy, toxic, in peripheral neurotoxic disorders, 683–686
in mood and affect disorders, 652–655
Methanol intoxication, 670–671
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication, 674–675
Methyl/mercury, brain maldevelopment caused by, 553–554
Migraine, stroke associated with, treatment of, 406–408
Milan automated neurobehavioral system, 596
Millon Behavior Checklist, 596
Minnesota Multiphasic Personality Inventory (MMPI), 596
Mitochondria, neuronal effect of, 519
Mitochondrial myopathies and encephalopathies, **105–123**
biochemistry of, 106–108, 111–112
cerebellar ataxia plus pigmentary retinopathy syndromes, 115
chronic progressive external ophthalmoplegia syndromes, 87–88, 113–114, 116
classification of, 82–83
diagnosis of, 108–112
DNA depletion diseases, 88, 115–116
exercise response in, 26–27, 29
Friedreich's ataxia, 118
genetics of. See *Genetics;* specific diseases.
hereditary spastic paraplegia with ragged-red fiber myopathy, 118
heteroplasmic, 58, 107
homoplasmic, 58, 107–108
inheritance of, 57–59
Kearns-Sayre disease, 113–114, 116
Leigh disease, 85–87, 115, 117–118
magnetic resonance techniques for, 39–44
metabolic testing for, 110
mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, 114–115
molecular diagnosis of, 81–88
myoclonic epilepsy and ragged-red fiber disease (MERRF), 114
myoglobinuria in, 221
myoneurogastrointestinal disorder and encephalopathy, 87, 116–117
pathology of, 110–111
phenotype recognition in, 109–110
treatment of, monitoring of, 43–44
Wolfram syndrome, 117
Mitochondrial pathway, 529–530
Mitochondrial toxicity, 708–710

Mitochondrial trifunctional protein deficiency, 75, 78–79, 180–181, 221
Mitral annular calcification, stroke associated with, 327
Mitral valve prolapse, stroke associated with, 327
MMPI. See *Minnesota Multiphasic Personality Inventory (MMPI).*
Molecular diagnosis, of metabolic myopathies, **53–104.** See also *Genetics.*
Mood, neurobiology of, 650–652
Mood disorders, toxins in, **649–664**
  arsenic, 654–655
  bismuth, 655
  carbon monoxide, 658–659
  chemicals, 656
  lead, 652–653
  manganese, 654
  medicolegal implications in, 659–661
  mercury, 653–654
  metals, 652–655
  organophosphates, 657–658
  organotins, 655
  solvents, 656–657
Mortality, in acyl-coenzyme A dehydrogenase deficiencies, 180
Motor unit action potentials, in acid maltase deficiency, 155
MPTP. See *1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication.*
MR diffusion imaging. See *Magnetic resonance (MR) diffusion imaging.*
MRA. See *Magnetic resonance angiography (MRA).*
MRI. See *Magnetic resonance imaging (MRI).*
Multiinfarct dementia, 860–861
Multiple sclerosis, exercise response in, 30–31
Muscle(s), biopsy of. See *Biopsy, muscle.*
  dissolution of, myoglobin production in. See *Myoglobinuria.*
  effects of toxins on, **695–717.** See also *Toxin(s), myopathy caused by.*
  enlargement of, in hypothyroid myopathy, 204
  evaluation of, magnetic resonance techniques for. See *Magnetic resonance spectroscopy and imaging, in metabolic myopathies.*
  metabolic disorders of. See *Metabolic myopathies.*
  metabolism of, effects of toxins on, 697, 700–701
  necrosis of, in myoglobinuria, 216–219, 230
  ragged-red fibers in. See *Ragged-red fibers.*
  response to exercise. See *Exercise, muscle responses to.*
  trauma to, myoglobinuria in, 225–226
Muscle fibers, morphologic changes of, in metabolic myopathies, 5–9
Muscular dystrophies, exercise response in, 28, 30
  myoglobinuria in, 221–222
  versus glycogen storage diseases, 143
Mushroom poisoning, 725–726
Mutations. See *Genetics.*
Myalgia, in metabolic myopathies, 2
  in myoadenylate deaminase deficiency, 188–189
  in myoglobinuria, 216
  in myophosphorylase deficiency, 130–131
  myotoxicity of, 712
Myasthenia gravis, repetitive nerve stimulation in, 609
Myelin, vulnerability of, 523–524
Myoadenylate deaminase deficiency, **185–194**
  acquired, 191–192
  asymptomatic, 188
  case histories of, 190–192
  clinical features of, 188–189
  coincidental inherited, 192
  diagnosis of, 88–89, 189–190
  genetic factors in, 88–89, 186–189
  historical aspects of, 185–187
  inherited, 191
  isoform variation in, 187
  pathophysiology of, 187–188
  prognosis for, 190
  treatment of, 190
Myocardial infarction, stroke associated with, 323
Myoclonic epilepsy and ragged-red fiber disease, 114
Myoedema, in hypothyroid myopathy, 204
Myoglobinuria, 2, 54, **215–243**
  causes of, 218–230
    acquired, 219, 222–230
    carnitine palmitoyltransferase deficiency, 176
    debranching enzyme deficiency, 128
    drugs, 222, 226–228
    electrolyte imbalance, 225
    exercise, 223–224
    fatty acid oxidation disorders, 220–221
    glycolysis or glycogenolysis disorders, 220
    hereditary, 219–222
    infections, 229
    mitochondrial disorders, 221
    myophosphorylase deficiency, 131
    nonmetabolic myopathies, 221–222
    phosphoglycerate kinase deficiency, 139
    phosphoglycerate mutase deficiency, 140–141

salt imbalance, 225
temperature extremes, 224–225
toxins, 222, 228–229
trauma, 225–226
water imbalance, 225
chemical structure and, 215
clinical features of, 216
complications of, 230
definition of, 215
differential diagnosis of, 143–144, 218–230
laboratory evaluation of, 216–217
myotoxicity of, 713
pathophysiology of, 217–218
treatment of, 230–232
Myoneurogastrointestinal disorder and encephalopathy (MNGIE), 87, 116–117
Myopathy(ies), alcohol, acute, 705
chronic, 705–706
focal, 714
in malignant hyperthermia, 713–714
in myalgia, 712
in myoglobinuria, 713
inflammatory, agents causing, 708
metabolic. See *Metabolic myopathies.*
occupational exposures and, 712
steroid, acute, 702–703
chronic, 702
toxin-induced, **695–717.** See also *Toxin(s), myopathy caused by.*
vacuolar, 710–711
Myophosphorylase deficiency, 130–134, 152
exercise response in, 23–26
magnetic resonance techniques in, 44–46
molecular diagnosis of, 62, 67
myoglobinuria in, 220
Myotonia, in metabolic myopathies, 2
in potassium-sensitive periodic paralysis, 199
Myotoxicity, potential, syndromes of, 712–714
Myxoma, atrial, stroke associated with, 323

Narcotic(s), myoglobinuria due to, 228
Near-infrared spectroscopy, in exercise testing, in metabolic myopathies, 22, 26–27
Necrosis, of muscle, in myoglobinuria, 216–219, 230
Needle electromyography. See *Electromyography.*
Nerve conduction studies, in acid maltase deficiency, 155
in branching enzyme deficiency, 160–161
in debranching enzyme deficiency, 158–159
in familial hypokalemic periodic paralysis, 196–197
in metabolic myopathies, 4
in potassium-sensitive periodic paralysis, 200
Nerve stimulation, repetitive, in metabolic myopathies, 4
in neurobehavioral toxicology evaluation, 609–610
Neural transplantation, following stroke, 504
Neurobehavioral testing, issues regarding, 544–548
Neurobehavioral toxicology, behaviors related to, measuring of, **579–599**
Neurochemical brain imaging, in neurotoxicology, 626
Neurofibrillary tangles, in Alzheimer's disease, 848–850
Neuroglia, vulnerability of, 523–524
Neuroimaging, in dementia, **885–901.** See also *Dementia, neuroimaging in.*
in frontotemporal dementia, 987–988
in neurotoxicology, **615–629**
applications of, 626–627
functional brain imaging in, 624–626
modalities of, 616–622
MRI in, 616–619
PET in, 621–622
processes in, 622–626
SPECT in, 619–621
structural brain imaging in, 623–624
x-ray CT in, 616
in stroke outcome, 460–467
in vascular dementia, 963–966
Neurological injury, behavioral effects of, 579–599. See also *Behavior, measuring of.*
Neuron(s), axonal maintenance and transport effects on, 522–523
energy state effects on, 519
enzyme inhibition effects on, 519
mitochondrial effects on, 519
neurotransmitter systems effects on, 520–522
processes of, 518–523
protein synthesis effects on, 519
somal DNA effects on, 518–519
vulnerability of, 518–523
Neuropathy(ies), drug-induced, 687–691
quantitative neurological examination of, 572–575
Neuropeptide(s), neuronal effect of, 522
Neuropharmacologic brain imaging, in neurotoxicology, 626
Neuroprotective drugs, following stroke, 499–501
in animals, inherent benefits and limitations of, 482–484

Neuroprotective drugs (*continued*)
translation to human studies, 484–489
versus humans, **475–493**
prophylactic, following stroke, 510
Neuropsychiatric disorders, in Alzheimer's disease, 830–831. See also *Alzheimer's disease, neuropsychiatric disorders in.*
Neuropsychological test battery, 596–598
Neurotoxic disorders, causes of, 632
peripheral, **681–694.** See also *Peripheral neurotoxic disorders.*
suspected, evaluation of, bias in, 633
case reports, 644
confidence intervals in, 638–639
confounding in, 636–638
epidemiologic principles in, **631–648**
epidemiologic studies in, 642–644
exposure assessment in, 639–641
healthy worker effect in, 634–635
outcome measures in, 641–642
significance testing in, 638–639
Neurotoxic exposures, developmental considerations of, **541–561**
Neurotoxic injury, apoptosis in, 532–533
mechanisms of, **525–540**
Neurotoxic responses, based on vulnerability of cellular sites, classification of, **517–524**
Neurotoxicity, glial cell injury in, 534–535
Neurotoxicologic studies, issues regarding, 544–548
Neurotoxicology, controversies in, **741–763**
Gulf War syndrome, 750–756
painters' encephalopathy, 742–746
silicone breast implants, 746–750
neuroimaging in, **615–629.** See also *Neuroimaging, in neurotoxicology.*
quantitative neurological examination in, **563–578.** See also *Quantitative neurological examination, in neurotoxicology.*
Neurotoxin(s), basal ganglia, **665–680.** See also *specific toxins and Basal ganglia neurotoxins.*
biological, **719–740**
animal toxins, 719–725
bacterial toxins, 730–736
botanical toxins, 725–740
future perspectives on, 736
developmental, drugs of abuse as, 545–552. See also *specific drug.*
environmental exposures as, 552–555
industrial, axonal transport affected by, 534
Neurotransmitter systems, neuronal effect of, 520–522
Neurotrophic agents, for Alzheimer's disease, 819–820
Nicotine, brain maldevelopment caused by, 545–546
Nicotinic acetylcholine receptor agonists, for Alzheimer's disease, 814
NINDS rt-PA stroke study, 383–388
Nitrofurantoin, neuropathies caused by, 688–689
3-Nitroproprionic acid intoxication, 672–674
Norepinephrine, neuronal effect of, 522
Nutrition, following stroke, in ICU, 445–446

Obesity, as factor in stroke in Hispanic Americans, 301
Occupational exposures, myopathy caused by, 712
OCTN2 gene, mutations of, carnitine deficiency in, 72, 173
Olfactory function, quantitative neurological examination of, 566–567
Oligodendrocyte(s), neuronal effect of, 524
Oligonucleotide analysis, allele-specific, in mutation detection, 60–61
Oncosis, 525–533
Ophthalmopathy, in hyperthyroidism, 205–206
Ophthalmoplegia, chronic progressive external, 87–88, 113–114, 116
in Kearns-Sayre disease, 113
in myoneurogastrointestinal disorder and encephalopathy, 87, 116–117
Opioid(s), myoglobinuria due to, 228
Organophosphate(s), in mood and affect disorders, 657–658
toxicity of, EEG in, 603
Organophosphorus compounds, neuropathies caused by, 691
Organotin(s), in mood and affect disorders, 655
Oxidative phosphorylation diseases. See *Mitochondrial myopathies and encephalopathies.*
Oxygen uptake, in exercise, 18–19

Paced auditory serial addition tests, 595
Paclitaxel, neuropathies caused by, 690
Pain, muscle. See *Myalgia.*
Painters' encephalopathy, controversies related to, 742–746
Paralysis, periodic. See *Periodic paralysis.*
tick, 722–723
Paralytic shell fish, 724
Paramyotonia, in potassium-sensitive periodic paralysis, 199
Paramyotonia congenita, 200–201

Paraplegia, spastic, with ragged-red fiber myopathy, 118
Paraplegin defects, in hereditary spastic paraplegia with ragged-red fiber myopathy, 118
Parathyroid gland, dysfunction of, myopathies in, 207–209
Parenchymal hypodensity, in stroke outcome, 462–463
Parenchymal intracerebral hemorrhage, described, 419
  prevalence of, 419
Parkinsonism, linked to chromosome 17, 859–860
Parkinson's disease, Alzheimer's disease with, and dementia with Lewy bodies, 856–857
  dementia in, **865–883.** See also *Dementia, in Parkinson's disease.*
  Lewy bodies and, 865–866
  neuropsychiatric features in, 868–869
Patent foramen ovale, stroke associated with, 324–325
Pearson's syndrome, 113
D-Penicillamine, myopathy caused by, 708
Perceptual functioning, neuropsychological evaluation of, 591–592
Perfusion-weighted imaging, in stroke outcome, 465–467
Periodic paralysis, **195–202**
  hypokalemic, 195–198
  potassium-sensitive, 198–200
  thyrotoxic, 206
Peripheral neurotoxic disorders, **681–694**
  arsenic in, 683–684
  clinical features of, 682–683
  heavy metal toxins in, 683–686
  lead in, 684–685
  mercury in, 685–686
  thallium in, 686
  vitamins in, 686–687
PET. See *Positron emission tomography (PET).*
PFKM gene, mutations of, 68–69
PGL genes, mutations of, 69, 71, 140
Phenylpropranolol, intracerebral hemorrhage caused by, 423
PHKA genes, mutations of, 139
Phosphate imbalance, myoglobinuria in, 225
Phosphocreatine, myopathy caused by, 701
Phosphofructokinase deficiency, 152
  exercise response in, 23–26
  magnetic resonance techniques in, 44–46
  molecular diagnosis of, 63, 68–69
  myoglobinuria in, 135–137, 220
Phosphoglycerate kinase deficiency, 139–140, 152
  molecular diagnosis of, 63, 69, 71
  myoglobinuria in, 220
Phosphoglycerate mutase deficiency, 140–141, 152
  molecular diagnosis of, 63, 71
  myoglobinuria in, 220
Phosphorus magnetic resonance spectroscopy, in metabolic myopathies, 35–37
  glycolytic, 44–47
  in exercise testing, 22
  mitochondrial, 40–42
  thyroid, 47
Phosphorylase b kinase deficiency, 137–139, 152
  exercise response in, 23–26
  molecular diagnosis of, 62, 68
  myoglobinuria in, 220
Phosphorylation, oxidative, disease of. See *Mitochondrial myopathies and encephalopathies.*
Pick's disease, 857–859
Pigmentary retinopathy, in Leigh disease, 115
Pittsburgh Occupational Exposure Test, 596
Pivampicillin, toxicity of, 710
Plant toxins, myoglobinuria due to, 229
Plaque(s), senile, in Alzheimer's disease, 850–852
Platelet count, in stroke outcome, 460
Poisoning, chickpea, 727–728
  khat, 728
  lead, EEG in, 603
  mushroom, 725–726
  myoglobinuria in, 222, 228–229
  with chlorinated hydrocarbons, EEG in, 603
Polychlorinated biphenyls, brain maldevelopment caused by, 554–555
Polyglucosan body disease (branching enzyme deficiency), 64, 66, 129–130, 152, 160–161
Pompe's disease. See *Acid maltase deficiency.*
Position, myoglobinuria related to, 226
Positron emission tomography (PET), in dementia, 886–890
  in neurotoxicology, 661–662
Posttraumatic stress disorder (PTSD), controversies related to, 570
Posturography, quantitative neurological examination, 571–572
Potassium channels, neuronal effect of, 520
Potassium deficiency, in familial hypokalemic periodic paralysis, 195–198
  myoglobinuria in, 225
Progressive nonfluent aphasia, and frontotemporal dementia, 983
Proportionality of injury, measuring of, 584–586

Prosthetic heart valves, stroke associated with, 326
Protein(s), Aβ, in Alzheimer's disease, production of, 905–908
Protein synthesis, inhibition, following stroke, neuroprotective drugs in, 500–501
  neuronal effect of, 519
Proton magnetic resonance spectroscopy, in metabolic myopathies, 37, 39, 42–43
Prourokinase, for stroke, 388–390
Psychotropic agents, for neuropsychiatric disorders in Alzheimer's disease, 839–842
Ptosis, in Kearns-Sayre disease, 113
Pyridoxine, in peripheral neurotoxic disorders, 687

Quail poisoning, myoglobinuria in, 229
Quantitative neurological examination, in neurotoxicology, **563–578**
  for mental status, 565–566
  for neuropsychiatric symptoms, 565
  for olfactory function, 566–567
  for tremor, 568–571
  for visual and auditory systems, 567–568
  neuropathy-related, 572–575
  posturography, 571–572
Quantitative sensory testing (QST), in neurobehavioral toxicology evaluation, 611–612

Race, as factor in stroke, 456
    incidence patterns, 296–298
    mortality patterns, 295–296
Ragged-red fibers, in hereditary spastic paraplegia with ragged-red fiber myopathy, 118
  in Kearns-Sayre disease, 113
  in mitochondrial myopathies, 110–111
  in myoclonic epilepsy and ragged-red fiber disease, 114
Recanalization, for stroke, 497
Recombinant tissue plasminogen activator (rt-PA), for stroke, 382–390
Referral information, in neuropsychological evaluation, 586–587
Reitan Aphasia Screening Test, 593
Reitan Klove Grip Strenth (Handynometer), 591
Reperfusion injury, following stroke, treatment of, 497–499
Reperfusion therapy, for stroke, 382–390, 497
Repetitive nerve stimulation, in neurobehavioral toxicology evaluation, 609–610
Research ethics, in dementia, 1013–1014
Respiratory chain disorders, myoglobinuria in, 221
Respiratory dysfunction, in Leigh disease, 115
Restriction fragment length polymorphisms, in mutation detection, 60
Retinopathy, in Leigh disease, 115
Rhabdomyolysis, myoglobin production in. See *Myoglobinuria.*
Ribose, in myoadenylate deaminase deficiency, 190
Rorschach test, 596

Saguenay Lac-Saint-Jean type of Leigh's disease, 117–118
Salt imbalance, myoglobinuria in, 225
Scandinavian Questionnaire 16, 565
Schwann cells, neuronal effect of, 524
Scorpion sting, 721
Seashore Rhythm and Tonal Memory Tests, 592
Seashore Rhythm Test, 595
Seizure(s), in mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), 114–115
  in myoclonic epilepsy and ragged-red fiber disease, 114
  myoglobinuria in, 224
Selection bias, defined, 633
Semantic dementia, 983–984
Senile plaques, in Alzheimer's disease, 850–852
Sensory functioning, neuropsychological evaluation of, 591–592
Sensory Perceptual Examination, 592
Serotonin, neuronal effect of, 522
Serum glucose, in stroke outcome, 460
Shell fish, paralytic, 724
Short-chain L-3-hydroxyacyl-coenzyme A dehydrogenase deficiency, 81
Sickle cell disease, in African Americans, 279–280
  stroke-related, treatment of, 409–410
Significance testing, in neurotoxic disorder evaluation, 638–639
Silicone breast implants, controversies related to, 746–750
Single-photon emission computed tomography (SPECT), in dementia, 886–890
  in neurotoxicology, 619–621
  in stroke outcome, 464

Single-strand conformation polymorphism, in mutation detection, 60
Smoking, as factor in stroke in Hispanic Americans, 301
  cigarette, as factor in stroke, 312–313
Snake envenomations, myoglobinuria in, 228
Snake venoms, 719–721
Sodium bicarbonate, in myoglobinuria, 231
Sodium channels, neuronal effect of, 520
Sodium imbalance, myoglobinuria in, 225
Solvent(s), in mood and affect disorders, 656–657
  myoglobinuria due to, 229
Solvent encephalopathy, controversies related to, 742–746
Spanish rapeseed oil, 728–729
Spastic paraplegia, with ragged-red fiber myopathy, 118
SPECT. See *Single-photon emission computed tomography (SPECT).*
Spectroscopy, magnetic resonance. See *Magnetic resonance spectroscopy and imaging.*
  near-infrared, 22, 26–27
Speech Sounds Perception Test, 592, 595
Sphingomyelin, 530–531
Spider bites, black widow, 724–725
  myoglobinuria due to, 229
Spiral CT angiography, in stroke, 367–368
Steroid myopathy, 209–211
Sting(s), scorpion, 721
Storage myopathies, glycogen. See *Glycogen storage diseases.*
  lipid. See *Lipid(s), oxidation of, disorders of.*
Streptokinase, for stroke, 382–390
Stroke
  aortic arch atheroma and, 328–329
  atrial fibrillation and, 321–323
  atrial myxoma and, 323
  atrial septal aneurysms and, 325–326
  cardioembolic, in African Americans, 278–279
  cardioembolism and, 321–329
  cigarette smoking and, 312–313
  death caused by, 309
  diabetes mellitus and, 311–312
  diagnosis of, **357–378**
    approach to, 357–358
    brain imaging in, 358–363
    cerebral angiography in, 363
    CT in, 358–359
    echocardiography in, 368–370
    hematologic testing in, 370–372
    holter monitor in, 370
    laboratory testing in, 370–372
    MR diffusion imaging in, 360–361
    MRA in, 366–367
    MRI in, 359
    spiral CT angiography in, 367–368
    transcranial Doppler ultrasound, 364–365
    ultrasonography in, 363–364
    vascular assessment in, 363–368
  DIC associated with, treatment of, 409
  dilated cardiomyopathy and, 324
  hematologic causes of, 408
  hematologic disorders associated with, treatment of, 408–410
  hemorrhagic, in African Americans, 277–278
  hypercoagulable states associated with, treatment of, 408–409
  hypertension and, 310–311
  in African Americans, **273–290**
    cardioembolic stroke, 278–279
    epidemiology of, 273–274
    extracranial and intracranial occlusive disease, 275–277
    functional outcome following, 284
    hemorrhagic stroke, 277–278
    incidence of, 274
    lacunar infarction, 277
    mortality associated with, 273–274
    prevalence of, 274
    prevention of, 280–283
    reasons for, 274–275
    risk factors for, cardiovascular, 274
      prevalence of, 274–275
      severity of, 275
    sickle cell disease, 279–280
    subtypes of stroke, 277–280
    vascular dementia and, 283–284
  in Hispanic Americans, **291–307**
    access to care and, 301–304
    age as factor in, 298–299
    alcohol abuse and, 301
    cardiac disease in, 300
    data sources for, 294–295
    death caused by, 291, 295–296
    definitions related to, 292–294
    diabetes mellitus in, 300
    future research on, 304
    gender in, 299
    hypertension in, 299–300
    lipids in, 300–301
    obesity in, 301
    risk factors for, 298–304
      behavioral versus genetic factors, 304–305
    smoking and, 301
    susceptibility to, 291
    tobacco use and, 301
  in mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), 114–115
  in progression, treatment of, in ICU, 446–447

Stroke (*continued*)
infective endocarditis and, 326–327
left ventricular thrombus and, 323–324
lipids and, 313–315
migraine, treatment of, 406–408
mitral annular calcification and, 327
mitral valve prolapse and, 327
myocardial infarction and, 323
nonatherosclerotic arteriopathies with, treatment of, 399–406
outcome following, age as factor in, 455–456
atrial fibrillation and, 456–457
blood pressure and, 457–458
body temperature and, 458
carotid duplex scanning in, 464
cerebrovascular risk factors in, 456–457
clinical findings in, 457–459
conventional angiography in, 464–465
CT angiography in, 463
CT in, 461–463
demographic factors in, 455–456
ethnicity as factor in, 456
gaze deviation and, 457
gender as factor in, 456
laboratory findings in, 459–460
level of consciousness and, 457
markers of tissue injury or inflammation and, 459–460
MRA in, 467
MRI in, 465–467
neuroimaging studies in, 460–467
platelet count and, 460
prediction of, stroke severity scales in, 458–459
predictors of, **455–473**
previosu stroke and, 456–457
race as factor in, 456
serum glucose and, 460
SPECT in, 464
transcranial Doppler ultrasound in, 463–465
patent foramen ovale and, 324–325
prevention of, **309–319, 321–341, 343–355,** 967–968
anticoagulants in, 352–353
secondary, 343–345
previous, as factor in stroke outcome, 456–457
prior, intracerebral hemorrhage caused by, 422
prosthetic heart valves and, 326
race and ethnic group incidence patterns of, 296–298
race and ethnic group mortality patterns of, 295–296
risk factors for, classification of, 309
sickle cell disease associated with, treatment of, 409–410
treatment of, **379–397, 399–417**
antiplatelet agents in, 392
antithrombotic, 390–393
combination therapies, 504–506
defibrinogenating agents in, 392–393
environment in, 503–504
facilitation of brain repair mechanisms in, 503–504
fundamentals of, 379–382
future of, **495–511**
growth factors in, 504
heparinoids in, 390–392
heparins in, 390–392
in ICU, **439–454**
airway management, 439–441
elevated ICP, 443–444
fever and infection management, 445
general medical management, 444–445
hemodynamic monitoring and therapy, 441–443
nutritional management, 445–446
sedation, 444–445
specialized monitoring, 447
intraarterial thrombolysis in, 388–390
intravenous thrombolytic therapy in, 382–388
neural transplantation in, 504
neuroprotective drugs in, 499–501
new era in, 495–497
prevention of endothelial activation and inflammation in, 497–499
recanalization in, 497
reperfusion in, 382–390, 497
stroke services in, organization of, 506
surgical, 447
valvular strands and, 327
Stroke severity scales, in prediction of stroke outcome, 458–459
Structural brain imaging, in neurotoxicology, 623–624
Structural lesions, intracerebral hemorrhage caused by, 422
Subacute necrotizing encephalopathy (Leigh disease), 115, 117–118
Succinate dehydrogenase, deficiency of, molecular diagnosis of, 84, 86
myoglobinuria in, 221
testing for, in mitochondrial myopathies, 111
Succinylcholine, myoglobinuria due to, 227
SURF genes, mutations of, in Leigh disease, 117–118
Swelling, in hypothyroid myopathy, 204
in myoglobinuria, 216
Symbol digit modality test, 595
Synaptic loss, in Alzheimer's disease, 853

Tactile Finger Localization, 592
Tactile Form Recognition, 592
Tactual Performance Test, 591
Tarui disease. See *Phosphofructokinase deficiency.*
TCA cycle, myopathy caused by, 700–701
Temperature extremes, myoglobinuria in, 224–225
Temperature gradient gel electrophoresis, in mutation detection, 59
Tetanus, 733–736
Tetany, in hypoparathyroid myopathy, 207
Thalidomide, in wasting syndrome, in HIV infection, 252
Thallium, in peripheral neurotoxic disorders, 686
The Smell Identification Test, 566
Thermogenesis, diet-induced, in chronic obstructive pulmonary disease, 246–247
Thrombolytic agents, intraarterial, for stroke, 388–390
  intravenous, for stroke, 382–388
Thrombosis, venous, cerebral, stroke-related, treatment of, 410–412
Thyroid dysfunction, myopathies in, 47, 203–207
Thyrotoxicosis, myopathies in, 205–207
Tick paralysis, 722–723
Ticlopidine, in stroke prevention, 348–349
Tissue injury, in stroke outcome, 459–460
Tissue wasting, **245–262**
  in chronic obstructive pulmonary disease, 245–249
  in congestive heart failure, 254–257
  in HIV infection, 249–254
Tobacco use, as factor in stroke in Hispanic Americans, 301
Total neuropathy score, 573
Toxin(s), animal, 719–725. See also *Animal toxins.*
  bacterial, 730–736. See also *Bacterial toxins.*
  botanical, 725–730. See also *Botanical toxins.*
  botulinum, 731–733
  ciguatera, 723–724
  heavy metal, in peripheral neurotoxic disorders, 683–686
  in mood and affect disorders, **649–664**
  myoglobinuria due to, 222, 228–229
  myopathy caused by, alcohol, 703–706
    clozapine, 711–712
    colchicine, 710–711
    corticosteroids, 701–703
    electron transport chain, 700–701
    evidence of, 695–697, 698–699
    extrinsic agents, 701
    glycogen metabolism, 700
    Krebs' cycle, 700–701
    lipid lowering agents, 706–708
    lipid metabolism, 700
    mechanisms of, 708–712
    metabolic, 697, 700–701
    phosphocreatine, 701
    TCA cycle, 700–701
    zidovudine, 708–709
Trail making test, 595
Transcranial Doppler ultrasonography, in stroke, 364–365
  in stroke outcome, 463–465
Transesophageal echocardiography, in stroke, 368–370
Transplantation, liver, in branching enzyme deficiency, 161
Transthoracic echocardiography, in stroke, 368–370
Trauma, muscle, myoglobinuria in, 225–226
Tremor(s), quantitative neurological examination of, 568–571
Trifunctional protein deficiency, 75, 78–79, 180–181, 221
Tumor necrosis factor-α, production of, in AIDS wasting syndrome, 253

Ultrasonography, in stroke, 363–364
  transcranial Doppler, in stroke, 364–365
    in stroke outcome, 463–465
Urine, acids in, in mitochondrial myopathies, 110
  myoglobin in. See *Myoglobinuria.*
Urokinase, for stroke, 388–390

Valproic acid, toxicity of, 710
Valvular strands, stroke associated with, 327
Vascular dementia, 780, **951–977.** See also *Dementia, vascular.*
  stroke and, in African Americans, 283–284
Vasculitis, treatment of, 406
Vasospasm, treatment of, 403–406
Venom(s), myoglobinuria due to, 228–229
  snake, 719–721
Venous thrombosis, cerebral, stroke-related, treatment of, 410–412
Ventilation, in exercise, 19
Vincristine, neuropathies caused by, 689
Visual Motor Gestaly Test, 592
Visual systems, quantitative neurological examination of, 567–568

Vitamin(s), B_6, in peripheral neurotoxic disorders, 687
in peripheral neurotoxic disorders, 686–687
von Gierke's disease, 152

Wasting syndrome, **245–262**
in chronic obstructive pulmonary disease, 245–249
in congestive heart failure, 254–257
in HIV infection, 249–254
Water imbalance, myoglobinuria in, 225
Weakness, in acid maltase deficiency, 154
in acyl-coenzyme A dehydrogenase deficiencies, 179–180
in adrenal dysfunction, 209–210
in aldolase deficiency, 142
in branching enzyme deficiency, 160
in carnitine deficiencies, 171–172
in carnitine palmitoyltransferase deficiency, 176
in debranching enzyme deficiency, 126, 158
in hyperparathyroid myopathy, 208
in hyperthyroid myopathy, 205
in hypothyroid myopathy, 204
in metabolic myopathies, 2
in myoadenylate deaminase deficiency, 185
in myoglobinuria, 216, 230
in myophosphorylase deficiency, 131
in paramyotonia congenita, 201
in phosphorylase b kinase deficiency, 138
in potassium-sensitive periodic paralysis, 199
Wechsler Memory Scale, 594
Weight loss, in chronic obstructive pulmonary disease, 246–248
in congestive heart failure, 254–256
in HIV infection, 249–250, 252
Western Aphasia Battery, 593
White matter, changes in, in dementia, 892–894
incomplete infarcts of, in vascular dementia, 964–966
Wisconsin Card Sorting Test, 593
Wolfram syndrome, 117
World Health Organizational Neurobehavioral Core Test Battery, 596

Xylitol, in myoadenylate deaminase deficiency, 190

Zalcitabine, toxicity of, 709
Zidovudine (AZT), toxicity of, 708–709